Del.icio.us
Google
Yahoo MyWeb
Facebook
Key People
Management
Cory Zwerling, President & CEO
No bio available. Add a bio.
Peter Daddona, Chief Scientific Officer
No bio available. Add a bio.
Greg Yedinak, Chief Manufacturing Officer, VP Manufacturing
No bio available. Add a bio.
Kim Gaumer, VP Regulatory Affairs and Quality Assurance
No bio available. Add a bio.
Gregory Yedinak, VP Manufacturing
No bio available. Add a bio.
Leslie Mesones, Director of Human Resources
No bio available. Add a bio.
M. Zwerling, President/CEO
No bio available. Add a bio.
Asha Ramdas, VP Product Development
No bio available. Add a bio.
Rebecca Sunshine, VP Human Resources
No bio available. Add a bio.
Board of Directors
Cory Zwerling
No bio available. Add a bio.
M. James Barrett
Dr. M. James Barrett joined New Enterprise Associates (NEA) in 2001 as a General Partner. He specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices, healthcare information systems and healthcare services companies. In addition to Predictive, he currently resides on the board of directors for Cardioxyl Pharmaceuticals, GlycoMimetics, Inc., Inhibitex, Inc. (NASDAQ: INHX), Nucleonics, Inc., Peptimmune, Inc., Proteostasis Therapeutics, Inc., Ruxton Pharmaceuticals, Sensors for Medicine and Science, Inc., Supernus Pharmaceuticals, Inc., Targacept, Inc. (NASDAQ: TRGT) and Zosano Pharma, Inc.
Prior to joining NEA, Jim served as Founder, Chairman and CEO of Sensors for Medicine and Science (1997 - 2001), where he remains Chairman. Prior to that, he led three NEA-funded companies, serving as Chairman and CEO of Genetic Therapy, Inc. (1987 - 1995), President and CEO of Life Technologies (1985 - 1987), and President and CEO of Bethesda Research Labs (1982 - 1983). Prior to 1982, he worked in various divisions of SmithKline.
Jim received his Ph.D. in Biochemistry at the University of Tennessee, his M.B.A. from the University of Santa Clara, and a B.S. in Chemistry from Boston College.
John Brown
No bio available. Add a bio.
Judith Hemberger
No bio available. Add a bio.
Mark Mitchnick
No bio available. Add a bio.
Mike Raab
Mike became a member of the Novalar board in 2007 as a representative of NEA. Mike joined NEA in 2002 as a Partner. He specializes in healthcare investments focusing on biotechnology and pharmaceutical sectors. In addition to Novalar, current board memberships include Amicus Therapeutics, CellGate, Hyperion, Intarcia, Novacea and Zosano Pharma. Mike is also actively involved with 23andMe, Trine Pharmaceuticals, Liquidia and Vitae Pharmaceuticals. As well, Mike is a member of the Life Sciences Advisory Board for Silicon Valley Bank. Prior to joining NEA, Mike was most recently Senior Vice President, Therapeutics and General Manager, of the Renal Division at Genzyme Corporation. Prior to that, Mike was Vice President of Business Development for the Therapeutics Division, responsible for the identification and in-licensing of new therapeutic product opportunities. He gained extensive international experience while building a commercial operation in Latin America for the Therapeutics and Surgical Products groups for the company. Mike was also Product Manager for Ceredase and was instrumental in the worldwide launch of Cerezyme, Genzyme's $1 billion therapy for Gaucher Disease. Mike also spent two years with Genzyme's Diagnostic products and services division. Previous to Genzyme, Mike held sales and marketing positions at Repligen and Bristol-Myers. Mike received his BA from DePauw University.
John P. Richard
No bio available. Add a bio.
Jee Shin
No bio available. Add a bio.
John Richard
No bio available. Add a bio.
Michael Raab
Mike Raab
Partner, NEA
Mr. Raab joined NEA in 2002 as a Partner. He specializes in healthcare investments focusing on biotechnology and pharmaceutical sectors. Current board memberships include Amicus Therapeutics (NASDAQ: FOLD), Intarcia, CellGate, Novacea (NASDAQ: NOVC), Hyperion, Novalar and Macroflux. Mr. Raab is a member of the Life Sciences Advisory Board for Silicon Valley Bank and is actively involved with 23andMe, Trine Pharmaceuticals, Liquidia and Vitae Pharmaceuticals.
Prior to joining NEA, Mr. Raab was most recently Senior Vice President, Therapeutics and General Manager, of the Renal Division at Genzyme Corporation. Prior to that, he was Vice President of Business Development for the Therapeutics Division, responsible for the identification and in-licensing of new therapeutic product opportunities. He gained extensive international experience while building a commercial operation in Latin America for the Therapeutics and Surgical Products groups for the company. Mr. Raab was also Product Manager for Ceredase and was instrumental in the worldwide launch of Cerezyme, Genzyme’s $1 Billion therapies for Gaucher Disease. Mr. Raab spent two years with Genzyme’s Diagnostic products and services division. Previous to Genzyme, he held sales and marketing positions at Repligen and Bristol-Myers.
Mr. Raab received his BA from DePauw University.
Similar Companies
View All Similar »
Profile
OpinionsNews & Blogs
View All News »- Latest
- Most Popular
- Submit a Story »
Zosano Pharma Raises $30M
Jul 8, 2009 - 0 comments
Zosano Pharma on Twitter
Twitter Search »Discussions
View All Discussions »There are no discussions right now.
Recent Contributors
There are no recent contributors to this company.